Efficacy and Safety of Actovegin in Post-stroke Cognitive Impairment (PSCI) "ARTEMIDA"


Phase 3 Results

Summary of Purpose

The aim of this trial is to provide evidence that Actovegin has a symptomatic effect in subjects with post stroke cognitive impairment (PSCI) during a six month treatment period compared to subjects administered placebo. Subjects received IV infusions whilst in hospital, and tablets once discharged. Subjects were followed up for a further six months after their treatment had been stopped to explore if the...

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 23 January 2016.

1 Jun 2012 20 Apr 2012 1 Nov 2014 1 Nov 2014 1 Jan 2016 23 Jan 2016
Start Date First Received 1st Completion Completion Verification Results

Trial Basics




Trial Design

  • Allocation: Randomized
  • Masking: Double Blind (Subject, Investigator)
  • Purpose: Treatment
  • Endpoint: Safety/Efficacy Study
  • Intervention: Parallel Assignment